Tudriqev Works by Replicating Inside Tumors to Trigger an Immune Response

Introduction

Replimune's Tudriqev (vusolimogene oderparepvec-wtpg) represents a different approach to cancer treatment by using a genetically engineered herpes simplex virus to attack tumors directly while also stimulating the body's immune system.

Unlike conventional drugs that primarily work through systemic exposure, Tudriqev is injected directly into tumors. Its mechanism is designed around a dual local-and-systemic effect: selective viral replication helps destroy tumor cells, while the resulting immune activation can potentially direct the body's defenses toward cancer cells elsewhere in the body.

An Engineered HSV-1-Based Therapy

Tudriqev is based on an engineered strain of herpes simplex virus type 1 (HSV-1).

The virus has been modified to enhance its ability to kill tumor cells and stimulate an immune response. Replimune's platform incorporates a fusogenic protein and GM-CSF, with the goal of increasing tumor-cell killing, making tumor-cell death more immunogenic, and activating a systemic anti-tumor immune response.

This places Tudriqev within the growing field of oncolytic immunotherapy, where engineered viruses are used not only to attack cancer cells directly but also to turn tumors into a source of immune stimulation.

Step 1: Tudriqev Is Injected Directly Into Tumors

The treatment is administered through intratumoral injection.

This delivery method allows the engineered virus to be placed directly inside accessible tumors rather than relying entirely on systemic circulation to reach cancerous tissue.

Replimune's platform is designed to allow injection into multiple types of lesions, including superficial and deeper tumors, with the aim of addressing different tumor sites and their local immune environments.

The direct injection is important because the therapy's mechanism begins within the tumor itself.

Step 2: The Virus Replicates Inside Tumor Cells

Once delivered into the tumor, Tudriqev is designed to replicate selectively within tumor cells.

Viral replication contributes to the destruction of infected cancer cells. As the virus reproduces and tumor cells are damaged or destroyed, tumor-derived material is released into the surrounding environment.

Earlier clinical research with RP1 showed evidence of robust virus replication within tumors, supporting the biological mechanism underlying the therapy.

This direct tumor-killing activity is the first component of Tudriqev's mechanism.

Step 3: Tumor Destruction Releases Cancer Antigens

The destruction of tumor cells has another important consequence.

When cancer cells die, they can release tumor-derived antigens and other signals that can be recognized by the immune system.

Replimune's platform is specifically designed to make tumor-cell death more immunogenic. In other words, the objective is not simply to destroy tumor cells but to make that destruction more visible to the immune system.

This creates a bridge between the local viral attack and the broader immune response.

Step 4: The Tumor Environment Becomes More Immune-Active

Tudriqev is also designed to alter the tumor microenvironment, which can otherwise suppress immune activity.

According to Replimune's mechanism-of-action data, RP1 can increase tumor-reactive T cells and promote a more immune-inflamed tumor environment. The FDA advisory committee briefing materials also describe evidence of changes in the tumor microenvironment following treatment.

This is particularly relevant in melanoma that has become resistant to previous immune checkpoint therapy, where tumors may have developed mechanisms that limit effective immune-cell activity.

Step 5: The Immune Response Can Extend Beyond the Injected Tumor

The most important part of Tudriqev's design is that its effects are intended to extend beyond the tumor that receives the injection.

As tumor cells are destroyed and tumor antigens are released, the immune system can be stimulated to recognize cancer-related targets. Activated immune cells can then potentially travel through the body and attack tumor cells at other sites.

This is why Replimune describes its platform as having a dual local and systemic mechanism of action: direct virus-mediated tumor killing is combined with activation of a broader anti-tumor immune response.

Evidence of Activity in Non-Injected Tumors

The clinical data provide support for this systemic component.

In the IGNYTE study, responses were observed not only in injected lesions but also in non-injected lesions. The FDA briefing materials noted that injected and non-injected lesions showed similar response characteristics in terms of frequency, durability, depth, and kinetics, supporting the interpretation that the treatment can generate systemic anti-tumor activity.

This is important because it suggests that Tudriqev's potential effect is not limited to physically destroying the tumor receiving the injection.

Why Nivolumab Is Used With Tudriqev

Tudriqev is approved for the relevant melanoma indication in combination with nivolumab, a PD-1 immune checkpoint inhibitor.

The scientific rationale is that Tudriqev can help create a more immune-active tumor environment, while PD-1 blockade can help prevent activated T cells from being suppressed.

FDA briefing materials describe RP1's mechanism in combination with anti-PD-1 therapy as increasing tumor-reactive T cells and promoting an immune-inflamed tumor microenvironment, potentially helping tumors become more responsive to checkpoint blockade.

The combination therefore aims to connect two mechanisms: viral tumor destruction and immune checkpoint release.

Biomarker Findings Support the Mechanism

Earlier clinical studies also produced biological evidence consistent with this approach.

Replimune reported increases in CD8 T cells and PD-L1 in serial tumor biopsies from patients treated with RP1. The company also reported evidence of robust viral replication within tumors.

These findings are important because they provide biological evidence supporting the proposed mechanism rather than relying solely on measurements of tumor shrinkage.

Why This Mechanism Matters in Immunotherapy-Resistant Melanoma

Tudriqev's mechanism is particularly relevant to patients whose melanoma has progressed after anti-PD-1 therapy.

If a tumor is poorly recognized or poorly infiltrated by immune cells, simply blocking PD-1 may not produce sufficient activity. Tudriqev is designed to generate a new immune stimulus inside the tumor by causing immunogenic tumor-cell destruction and releasing tumor antigens.

The objective is therefore not simply to add another checkpoint inhibitor, but to change the tumor environment so that the immune system has more targets and greater opportunity to respond.

A Different Model of Oncolytic Immunotherapy

Tudriqev illustrates how oncolytic viruses are being developed as more than traditional cancer-killing agents.

The approach can be viewed as a sequence:

Tumor injection → viral replication → tumor-cell destruction → antigen release → immune activation → systemic anti-tumor response

Each step contributes to the overall therapeutic strategy.

This dual mechanism is one reason oncolytic immunotherapy has attracted interest as a potential partner for established immune checkpoint therapies.

Mechanism Still Needs to Translate Into Confirmed Clinical Benefit

While the biological rationale is compelling, mechanism alone does not establish clinical effectiveness.

Tudriqev received accelerated FDA approval based on clinical evidence showing objective responses and duration of response. The treatment's ongoing Phase 3 IGNYTE-3 trial is intended to provide additional comparative evidence and verify clinical benefit.

That distinction is important: evidence that a therapy replicates in tumors and activates immune pathways supports its scientific rationale, but randomized clinical evidence is needed to establish how much that mechanism ultimately improves patient outcomes.

Conclusion

Tudriqev's mechanism combines direct viral tumor destruction with systemic immune activation.

The engineered HSV-1-based therapy is injected into tumors, where it is designed to replicate, destroy cancer cells, release tumor antigens, and alter the tumor microenvironment. These effects are intended to activate immune cells that can recognize and attack cancer beyond the injected tumors.

When combined with nivolumab, the strategy is designed to make the tumor environment more favorable for an anti-cancer immune response while reducing immune suppression through PD-1 blockade.

For Replimune, the central question now is whether this sophisticated biological mechanism translates into durable and confirmed clinical benefit. The ongoing Phase 3 program will provide the next major test of whether Tudriqev's virus-plus-immunity approach can establish a lasting role in advanced melanoma treatment.